drugset / Trial / NCT00038493
Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will combine the chemotherapy agent temozolomide with the investigational drug SCH66336 (an agent which interferes with new cell growth). Patients will be treated with oral temozolomide on days 1-5 and oral SCH66336 on days 8-28 every 28 days.
Timeline
- Start
- 2001-09-21
- Primary completion
- 2005-08-01
- Completion
- 2005-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lonafarnib | Small molecule | 150 mg | Oral |
| Subject | Temozolomide | Small molecule | 150 mg/m2 | Oral |
| Subject | Temozolomide | Small molecule | 200 mg/m2 | Oral |